ROIV News and Press, Roivant Sciences Ltd. From 11/27/23

2023-11-27 11:19:40 ET More on Roivant Sciences Roivant Sciences Ltd. (ROIV) Q2 2023 Earnings Call Transcript Roivant Sciences Ltd. 2023 Q2 - Results - Earnings Call Presentation Roivant Sciences: Risk-Transforming Deal Met With Crickets Biggest stock movers ...

2023-11-27 08:12:58 ET More on pre-market losers stock. Financial information for Anghami Financial information for Safe and Green Development Corporation For further details see: ANGH and SGD among pre-market losers

Oral brepocitinib failed to meet its primary endpoint of Systemic Lupus Erythematosus Responder Index (SRI-4) change of 4 at Week 52 Priovant plans to continue progressing the program in indications outside of Systemic Lupus Erythematosus (SLE) given the drug’s favorable safety and tol...

2023-11-13 19:19:09 ET Roivant Sciences Ltd. (ROIV) Q2 2023 Earnings Conference Call November 13, 2023 8:00 AM ET Company Participants Stephanie Lee - Vice President, Special Projects Matt Gline - Chief Executive Officer Mayukh Sukhatme - President and Chief Inve...

2023-11-13 07:03:26 ET More on Roivant Sciences Roivant Sciences: Risk-Transforming Deal Met With Crickets Skin In The Game: Behind Roivant's Significant Rise Roivant Sciences Q2 2024 Earnings Preview Biggest stock movers today: Chevron, EngageSmart, Crypto-f...

Roivant entered into a definitive agreement with Roche for the sale of Telavant for $7.1B upfront and a milestone payment of $150M payable upon the initiation of a Phase 3 trial in ulcerative colitis IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are ...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Roivant Sciences Ltd. (ROIV) is expected to report $-0.32 for Q2 2024

2023-11-10 12:16:42 ET More on Roivant Sciences Roivant Sciences: Risk-Transforming Deal Met With Crickets Skin In The Game: Behind Roivant's Significant Rise Roivant Sciences Ltd. (ROIV) Q1 2023 Earnings Call Transcript Biggest stock movers today: Chevron, E...

BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately. Dr. Sukhatme will fill a newly created Class III seat on the Board of Directors, increas...